Last reviewed · How we verify

Rezulin (TROGLITAZONE)

Pfizer · FDA-approved withdrawn Small molecule Quality 30/100

Rezulin (TROGLITAZONE) is a small molecule drug developed by Pfizer Pharmaceuticals that targets the Forkhead box protein M1. It belongs to the troglitazone class and was approved by the FDA in 1997 for the treatment of type 2 diabetes mellitus. Although it is off-patent, it is still owned by Pfizer Pharmaceuticals. Rezulin works by activating the peroxisome proliferator-activated receptor gamma (PPAR-γ), which regulates glucose and lipid metabolism. However, due to safety concerns, its use has been limited.

At a glance

Generic nameTROGLITAZONE
SponsorPfizer
Drug classtroglitazone
TargetForkhead box protein M1
ModalitySmall molecule
Therapeutic areaMetabolic
PhaseFDA-approved
First approval1997

Approved indications

Common side effects

No common side effects on file.

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results